Active Ingredient History
Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Allergy and Immunology (Phase 1/Phase 2)
Alzheimer Disease (Phase 2)
Amyloid (Phase 2)
Amyloidosis (Phase 2)
Anemia, Aplastic (Phase 1)
Anemia, Hemolytic (Phase 1)
Autoimmune Diseases (Phase 1/Phase 2)
Blood Protein Disorders (Phase 1/Phase 2)
Blood Transfusion (Phase 1)
Breast Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Early Phase 1)
Carcinoma, Transitional Cell (Early Phase 1)
Chromosome Disorders (Phase 2)
Colorectal Neoplasms (Phase 2)
Corneal Diseases (Phase 1/Phase 2)
Drugs, Investigational (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Glomerulonephritis (Phase 2)
Graft Rejection (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 1)
Heart Transplantation (Phase 2)
Hematologic Diseases (Phase 1)
Hematology (Phase 1/Phase 2)
Hemophilia A (Phase 4)
Hodgkin Disease (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Phase 3)
Inosine Triphosphate (Phase 2)
Kidney Neoplasms (Early Phase 1)
Kidney Transplantation (Phase 1/Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 1)
Leukemia, Myeloid (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lupus Nephritis (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Lymphoma, Primary Effusion (Phase 2)
Lymphoma, T-Cell (Phase 2)
Mycosis Fungoides (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 1/Phase 2)
Neoplasms ()
Neoplasms, Plasma Cell (Phase 1/Phase 2)
Nephrotic Syndrome (Phase 2)
Neuromyelitis Optica (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Paraproteinemias (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Plasmablastic Lymphoma (Phase 2)
Plasmacytoma (Phase 2)
POEMS Syndrome (Phase 2)
Prostatic Neoplasms (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Early Phase 1)
Recurrence (Phase 2)
Renal Insufficiency (Phase 2)
Smoldering Multiple Myeloma (Phase 3)
Testosterone (Phase 1)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
